RxDoctor Payments Data

Heather Holden, MD

Rheumatology · Charlotte, NCNPI 1023296670

Payments from drug & device makers

$6,614in general payments, 2019–2025

Across 321 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$1K
  • Johnson & Johnson$678
  • UCB, Inc.$624
  • E.r. Squibb & Sons, L.L.C.$349
  • Novartis$268
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,47298%
  • Education$1422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,614 in reported general payments places this provider in the 55th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,618,444
Medicare patients
505
Services billed
99,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept26$282,519
Cosentyx Sensoready PenSecukinumab18$161,815
Xeljanz XrTofacitinib Citrate26$147,184
Cosentyx Unoready PenSecukinumab11$141,412
OrenciaAbatacept15$136,180
Taltz SyringeIxekizumab12$86,058
SimponiGolimumab11$76,125
BenlystaBelimumab15$68,270
OrenciaAbatacept/Maltose11$47,006
Hydroxychloroquine Sulfate364$15,279
Mycophenolate Mofetil63$9,088
MethotrexateMethotrexate Sodium245$6,659
Leflunomide105$4,815
Celecoxib138$3,067
Prednisone364$2,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Orencia, Orencia$349$183,18526 claims
Johnson & JohnsonSimponi$678$76,12511 claims
GSKBenlysta$184$68,27015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →